Killeen Trevor F, Shanley Ryan, Ramesh Vidhyalakshmi, Giubellino Alessio
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
Masonic Cancer Center-Biostatistics Core, University of Minnesota, Minneapolis, MN 55455, USA.
Cancers (Basel). 2023 Jul 13;15(14):3600. doi: 10.3390/cancers15143600.
Malignant melanoma is the leading cause of death due to cutaneous malignancy. Immunocompromised individuals have an elevated risk of developing melanoma. We aimed to provide histopathologic and statistical characterization of melanoma development in immunocompromised patients.
We reviewed our institution's databases to identify all patients with a confirmed history of immunosuppression who subsequently developed melanoma, focusing on diagnoses during the follow-up period of 2011-2019. A total of 93 patients with a combined 111 melanoma lesions were identified.
Common causes of immunosuppression included transplantation and lymphoproliferative disorders. Superficial spreading and lentigo malignant melanoma were the most common malignant melanoma subtypes. Median Breslow depth was 0.7 mm, and the most common primary tumor stage was T1a. Our transplant sub-cohort had an overall melanoma incidence of 0.9 per 1000 person-years (95% CI 0.66 to 1.20) and a standardized incidence ratio (SIR) of 1.53 (95% CI 1.12 to 2.04) relative to a general population cohort from the Surveillance, Epidemiology, and End Results Program (SEER).
We report histopathologic characteristics of immunocompromised patients developing melanoma at a large academic tertiary-care center. Differences in age, sex, time since transplantation, and transplant type may play a significant role in melanoma SIR in this patient demographic.
恶性黑色素瘤是皮肤恶性肿瘤导致死亡的主要原因。免疫功能低下的个体患黑色素瘤的风险升高。我们旨在提供免疫功能低下患者黑色素瘤发生的组织病理学和统计学特征。
我们查阅了本机构的数据库，以确定所有有免疫抑制确诊病史且随后发生黑色素瘤的患者，重点关注2011 - 2019年随访期间的诊断情况。共确定了93例患者，其合并有111处黑色素瘤病灶。
免疫抑制的常见原因包括移植和淋巴增殖性疾病。浅表扩散型和雀斑样恶性黑色素瘤是最常见的恶性黑色素瘤亚型。中位 Breslow 深度为0.7mm，最常见的原发肿瘤分期为T1a。我们的移植亚组黑色素瘤总体发病率为每1000人年0.9例（95%可信区间0.66至1.20），相对于监测、流行病学和最终结果计划（SEER）的一般人群队列，标准化发病率（SIR）为1.53（95%可信区间1.12至2.04）。
我们报告了在一家大型学术三级医疗中心发生黑色素瘤的免疫功能低下患者的组织病理学特征。年龄、性别、移植后时间和移植类型的差异可能在该患者人群的黑色素瘤SIR中起重要作用。
